Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

https://pubmed.ncbi.nlm.nih.gov/32888407/

Authors: Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al.

Lancet 2020;396(10254):839-852.